🔮 OOTWOracle · All predictions · Odds sheet · Track record · Benchmark

FDA will require durability/maintenance data as a condition before any psilocybin-depression approval decision.

Predicted 2026-07-11 · Resolves 2027-06-30 · regulatory · USA

72%

ORACLE CONFIDENCE

⏳ Pending

Every outcome is scored publicly in the ledger.

Before the FDA (the US drug regulator) approves any psilocybin treatment for depression, it will likely require companies to show that patients stay better over time — not just that they felt better right after a session. This is a significant hurdle because most psilocybin studies so far have only tracked patients for a few weeks or months. Companies will need longer, harder studies to clear this bar.

Resolution rule: YES if, by 2027-06-30, any FDA action document (advisory committee briefing packet, Complete Response Letter summary, or approval letter) for a psilocybin depression NDA explicitly cites durability/maintenance/relapse data as a required or pivotal factor. Checked via fda.gov (Drugs advisory committee materials and Drugs@FDA). NO if a psilocybin depression decision is issued without such citation, or no decision occurs (resolves NO/void per no-decision).

Rapid remission with uncertain durability is the central weakness in every psilocybin readout. Acute effect alone is insufficient for approval; the division's stated stance requires relapse/maintenance framing. This is falsifiable via any FDA advisory-committee briefing document or complete-response/approval letter that either does or does not cite durability as a condition.

5 new falsifiable predictions, every day at 12:05 PM ET.

Get tomorrow's Oracle →